The CD11a binding site of efalizumab in psoriatic skin tissue as analyzed by multi-epitope ligand cartography robot technology: Introduction of a novel biological drug-binding biochip assay

Skin Pharmacology and Physiology

Volumn 20, Issue 2, 2007, Pages 96-111

  Bonnekoh, B ^a,d   Bockelmann R ^a   Pommer, A J ^b,c   Malykh, Y ^b   Philipsen, L ^b   Gollnick, H ^a  

^a OTTO VON GUERICKE UNIVERSITY   (Germany)

^b MelTec GmbH and Co KG   (Germany)

^c SkinSysTec GmbH   (Germany)

^d University Clinic for Dermatology and Venerology   (Germany)

Author keywords

Efalizumab (Raptiva ); Multiplex fluorescence immunophenotyping; Proteomics; Psoriasis; Toponomics

Indexed keywords

CD3 ANTIGEN; CD4 ANTIGEN; CD45RO ANTIGEN; CD8 ANTIGEN; EFALIZUMAB; INTERCELLULAR ADHESION MOLECULE 1; LYMPHOCYTE FUNCTION ASSOCIATED ANTIGEN 1;

ADULT; ANTIGEN SPECIFICITY; ARTICLE; BINDING SITE; BIOCHIP; CELL ADHESION; CELL COMPARTMENTALIZATION; CELL FUNCTION; CELL PROLIFERATION; CELL TYPE; CHEMICAL LABELING; CLINICAL ARTICLE; CONTROLLED STUDY; DERMIS; DISEASE ACTIVITY; DRUG BINDING; DRUG MECHANISM; DRUG RESPONSE; DRUG TARGETING; EX VIVO STUDY; FEMALE; HUMAN; HUMAN TISSUE; INFLAMMATION; LEUKOCYTE ADHERENCE; LYMPHOCYTE MIGRATION; MALE; MEMORY T LYMPHOCYTE; METHODOLOGY; MULTI EPITOPE LIGAND CARTOGRAPHY ROBOT TECHNOLOGY; NATURAL KILLER CELL; PRIORITY JOURNAL; PROTEOMICS; PSORIASIS; PSORIASIS VULGARIS; SKIN CULTURE; SKIN DEFECT; T LYMPHOCYTE; TECHNOLOGY; TREATMENT RESPONSE;

ADULT; AGED; ANTIBODIES, MONOCLONAL; ANTIGENS, CD11A; BINDING SITES; EPITOPES; FEMALE; FLUORESCEIN-5-ISOTHIOCYANATE; FLUORESCENT DYES; HUMANS; IMMUNOLOGIC FACTORS; MALE; MIDDLE AGED; MODELS, BIOLOGICAL; PROTEOMICS; PSORIASIS; ROBOTICS; SKIN; T-LYMPHOCYTES;

EID: 33846790927     PISSN: 16605527     EISSN: None     Source Type: Journal    
DOI: 10.1159/000097982     Document Type: Article

References (45)

1. Jullien D, Prinz JC, Langley RGB, Caro I, Dummer W, Joshi A, et al: T-cell modulation for the treatment of chronic plaque psoriasis with efalizumab (Raptiva™): mechanisms of action. Dermatology 2004;208:297-306.
2. Leonardi CL: Efalizumab, an overview. J Am Acad Dermatol 2003;49(suppl 2):S98-S104.
3. Marecki S, Kirkpatrick P: Efalizumab. Nat Rev Drug Discov 2004;3:473-474.
4. Papp K, Bissonnette R, Krueger JG, Carvey W, Gratton D, Gulliver WP, Lui H, Lynde CW, Magee A, Minier D, Ouellet JP, Patel P, Shapiro J, Shear NH, Kramer S, Walicke P, Bauer R, Dedrick RL, Kim SS, White M, Garovoy MR: The treatment of moderate to severe psoriasis with a new anti-CD11a monoclonal antibody. J Am Acad Dermatol 2001;45:665-674.
5. Werther WA, Gonzalez TN, O'Connor SJ, McGabe S, Chan B, Hotailing T: Humanization of an anti-lymphocyte function-associated antigen (LFA)-1 monoclonal antibody and reengineering of the humanized antibody for binding to rhesus LFA-1. J Immunol 1996;157:4986-4995.
6. Boehncke WH, Schon MP, Giromoforni G, Bos JD, Thestrup-Pedersen K, Cavani A, Nestle FO, Bonish BK, Campbell JJ, Nickoloff BJ: Leukocyte extravasation as a target for anti-inflammatory therapy - which molecule to choose? Exp Dermatol 2005;14:70-80.
7. Cather JC, Cather JC, Menter A: Modulating T-cell responses for the treatment of psoriasis: a focus on efalizumab. Expert Opin Biol Ther 2003;3:361-370.
8. Dustin ML, Springer TA: Lymphocyte function-associated antigen-1 (LFA-1) interaction with intercellular adhesion molecule-1 (ICAM-1) is one of at least three mechanisms for lymphocyte adhesion to cultured endothelial cells. J Cell Biol 1988;107:321-331.
9. Dustin ML, Springer TA: Role of lymphocyte adhesion receptors in transient interactions and cell locomotion. Annu Rev Immunol 1991;9:27-66.
10. Sanders ME, Makgoba MW, Sharrow SO, Stephany D, Springer TA, Young HA: Human memory T-lymphocytes express increased levels of the three cell adhesion molecules (LFA-3, CD2, and LFA-1) and three other molecules (UVHL1, CDw29 and Pgp-1) and have enhanced IFN-γ production. J Immunol 1986;140:1401-1407.
11. Gordon KB, Papp KA, Hamilton TK, Walicke PA, Dummer W, Li N, Breshnahan BW, Menter A: Efalizumab for patients with moderate to severe plaque psoriasis: a randomized controlled trial. J Am Med Assoc 2003;290:3073-3080.
12. Jordan JK: Efalizumab for the treatment of moderate to severe plaque psoriasis. Ann Pharmacother 2005;39:1476-1482.
13. Lebwohl M, Trying SK, Hamilton TK, Toth D, Glazer S, Tawfik NH, Walicke P, Dummer W, Wang X, Garovoy MR, Pariser D: A novel targeted T-cell modulator, efalizumab, for plaque psoriasis. New Engl J Med 2003;349:2004-2013.
14. Smith CH, Anstey AV, Barker JNWN, Burden AD, Chalmers RJG, Chandler D, Finlay AY, Grifitths CEM, Jackson K, McHugh NJ, McKenna KE, Reynolds NJ, Ormerod AD: British association of dermatologists guidelines for use of biological interventions in psoriasis 2005. Br J Dermatol 2005;153:486-497.
15. Menter A, Kosinski M, Bresnahan BW, Papp KA, Ware JE Jr: Impact of efalizumab on psoriasis-specific patient-reported outcomes. Results from three randomized placebo-controlled clinical trials of moderate to severe plaque psoriasis. J Drugs Dermatol 2004;3:27-38.
16. Leonardi CL, Papp KA, Gordon KB, Menter A, Feldman SR, Caro I, Walicke PA, Compton PG, Gottlieb AB: Extended efalizumab therapy improves chronic plaque psoriasis: results from a randomized phase III trial. J Am Acad Dermatol 2005;52:425-433.
17. Cather JC, Menter A: Efalizumab: continuous therapy for chronic psoriasis. Expert Opin Biol Ther 2005;5:393-403.
18. Gottlieb AB, Gordon KB, Lebwohl MG, Caro I, Walicke PA, Li N, Leonardi CL: Extended efalizumab therapy sustains efficacy without increasing toxicity in patients with moderate to severe chronic plaque psoriasis. J Drugs Dermatol 2004;3:614-624.
19. Menter A, Gordon K, Carey W, Hamilton T, Glazer S, Caro I, Li N, Gulliver W: Efficacy and safety observed during 24 weeks of efalizumab therapy in patients with moderate to severe plaque psoriasis. Arch Dermatol 2005;141:31-36.
20. Schubert W, Bonnekoh B, Pommer AJ, Philipsen L, Böckelmann R, Malykh Y, Gollnick H, Friedenberger M, Bode M, Dress AW: Analyzing proteome topology and function by automated multi-dimensional fluorescence microscopy. Nat Biotechnol 2006;24:1270-1278.
21. Perfetto SP, Chattopadhyay PK, Roederer M: Seventeen-colour flow cytometry: unraveling the immune system. Nat Rev Immunol 2004;4:648-655.
22. Franssen ME, Boezemann JB, Van de Kerkhof PC, Van Erp PE: Monitoring hyperproliferative disorders in human skin: flow cytometry of changing cytokeratin expression. Cytometry 2004;57B:32-39.
23. Goedkop AY, de Rie MA, Teunissen MBM, Picavet DI, van der Hall PO, Bos JD, Tak PP, Kraan MC: Digital image analysis for the evaluation of the inflammatory infiltrate in psoriasis. Arch Dermatol Res 2005;297:51-59.
24. Benjamin RJ, Qin SX, Wise MP, Cobbold SP, Waldmann H: Mechanisms of monoclonal antibody-facilitated tolerance induction: a possible role for the CD4 (L3T4) and CD11a (LFAS-1) molecules in self-non-self discrimination. Eur J Immunol 1988;18:1079-1088.
25. Cavazzana-Calvo M, Sarnacki S, Haddad E, De Coene C, Calise D, Yvon E, Cerf-Bensussan N, Fischer A: Prevention of bone marrow and cardiac graft rejection in an H-2 haplotype disparate mouse combination by an anti-LFA-1 antibody. Transplantation 1995;59:1576-1582.
26. He Y, Mellon J, Apte R, Niederkorn JY: Effect of LFA-1 and ICAM-1 antibody treatment on murine corneal allograft survival. Invest Opthalmol Vis Sci 1994;35:3218-3225.
27. Isobe M, Yagita H, Okumura K, Ihara A: Specific acceptance of cardiac allograft after treatment with antibodies to ICAM-1 and LFA-1. Science 1992;255:1125-1127.
28. Gordon EJ, Myers KL, Dougherty JP, Rosen H, Ron Y: Both efalizumab (LFA-1) and anti-CD11b (MAC-1) therapy delay the onset and diminish the severity of experimental autoimmune encephalomyelitis. J Neuroimmunol 1995;62:153-160.
29. Gauvreau GM, Becker AB, Bouklet LP, Chakir J, Fick RB, Greene WL, Killian KJ, O'Byrne PM, Reid JK, Cockcroft DW: The effects of an anti-CD11a mAB, efalizumab, on allergen-induced airway responses and airway inflammation in subjects with atopic asthma. J Allergy Clin Immunol 2003;112:331-338.
30. Goffe BS: Disseminated granuloma anulare resolved with the T-cell modulator efalizumab. Arch Dermatol 2004;140:1287-1288.
31. Bauer RJ, Dedrick RL, White ML, Murray MJ, Garovoy MR: Population pharmacokinetics and pharmacodynamics of the anti-CD11a antibody hu1124 in human subjects with psoriasis. J Pharmacokinet Biopharm 1999;27:397-420.
32. Coffey GP, Fox JA, Pippig S, Palmieri S, Reitz B, Gonzalez M, Bakshi A, Padilla-Eagar J, Fielder PJ: Tissue distribution and receptor-mediated clearance of anti-CD11a antibody in mice. Drug Metab Dispos 2005;33:623-629.
33. Mortensen DL, Walicke PA, Wang X, Kwon P, Kuebler P, Gottlieb AB, Krueger JG, Leonardi C, Miller B, Joshi A: Pharmacokinetics and pharmacodynamics of multiple weekly subcutaneous efalizumab doses in patients with plaque psoriasis. J Clin Pharmacol 2005;45:286-298.
34. Ng CM, Joshi A, Dedrick RL, Garovoy MR, Bauer RJ: Pharmacokinetic- pharmacodynamic-efficacy analysis of efalizumab in patients with moderate to severe psoriasis. Pharm Res 2005;22:1088-1100.
35. Gottlieb AB, Krueger JG, Bright R, Ling M, Lebwohl M, Kang S, Feldman S, Spellman M, Wittkowski K, Ochs HD, Jardieu P, Bauer R, White M, Dedrick R, Garovoy M: Effects of administration of a single dose of a humanized monoclonal antibody to CD11a on the immunobiology and clinical activity of psoriasis. J Am Acad Dermatol 2000;42:428-435.
36. Coffey GP, Stefanich E, Palmieri S, Eckert R, Padilla-Eagar J, Fielder PJ, Pippig S: In vitro internalization, intracellular transport, and clearance of an anti-CD11a antibody (Raptiva) by human T-cells. J Pharmacol Exp Ther 2004;310:896-904.
37. Boehncke WH, Ochsendorf FR, Noll S, Urban M, Popp A, Waldherr D, Haunschild J: Efficacy of the fully human monoclonal antibody MOR102 (#5) against intercellular adhesion molecule 1 in the psoriasis-severe combined immunodeficient mouse model. Br J Dermatol 2005;153:758-766.
38. Ellis CN, Krueger GG; Alefacept Clinical Study Group: Treatment of chronic plaque psoriasis by selective targeting of memory effector T-lymphocytes. N Engl J Med 2001;345:248-255.
39. Böckelmann R, Horn T, Gollnick H, Bonnekoh B: Interferon-γ- dependent in vitro model for the putative keratin 17 autoimmune loop in psoriasis: exploration of pharmaco- and gene-therapeutic effects. Skin Pharmacol Physiol 2005;18:42-54.
40. Böckelmann R, Neugebauer P, Paseban ND, Hüttemann M, Gollnick H, Bonnekoh B: Suprabasal overexpression of the hsRPB7 gene in psoriatic epidermis as identified by a reverse transcriptase-polymerase chain reaction differential display model comparing psoriasis plaque tissue with peritonsillar mucosa. Am J Pathol 2001;158:367-372.
41. Bonnekoh B, Gollnick H: Psoriasis; in Katsambas AD, Lotti TM (eds): European Handbook of Dermatological Treatment, ed 2. Berlin, Springer, 2003, pp 433-450.
42. Johnston A, Gudjonsson JE, Sigmundsdottir H, Love TJ, Valdimarsson H: Peripheral blood T-cell responses to keratin peptides that share sequences with streptococcal M proteins are largely restricted to skin homing CD8(+) T-cells. Clin Exp Immunol 2004;138:83-93.
43. Walsh SRA, Shear NH: psoriasis and the new biologic agents: interrupting a T-AP dance. Can Med Assoc J 2004;170:1933-1941.
44. Krueger JG, Bowcock A: Psoriasis pathophysiology: current concepts of pathogenesis. Ann Rheum Dis 2005;64(suppl 2):ii30-ii36.
45. Nickoloff BJ, Nestle FO: Recent insights into the immunopathogenesis of psoriasis provide new therapeutic opportunities. J Clin Invest 2004;113:1664-1675.